ReoPro GPIIb/IIIa inhibitor of platelet aggregation data

Follow-up results of the Phase III EPIC trial of ReoPro were published in the Journal of the American Medical Association, showing an improved outcome at three years.

Read the full 277 word article

How to gain access

Continue reading with a
two-week free trial.